| Autor: |
Haoxuan Chen, Zhenzhen Lou, Yibo Zhan, Huiying Ouyang, Guixian Chen, Changlin Zhang, Hui Mao, Xiaojun Li, Zhiping Huang, Longlong Wen, Haoyou Xu, Zequan Zheng, Yuanqi Zhao, Min Zhao |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Neurology Asia. 27:835-843 |
| ISSN: |
1823-6138 |
| Popis: |
Background: Admission hyperglycemia is a predictor of poor prognosis after ischemic stroke (IS). Previous studies have found that admission hyperglycemia was related to clopidogrel high on-treatment platelet reactivity (HTPR) in diabetic patients with myocardial infarction. However, reports on associations between admission hyperglycemia and clopidogrel HTPR remain scarce in IS patients. In this study, we assessed the correlation between admission hyperglycemia and clopidogrel HTPR in patients with IS. Methods: In this retrospective study, we included IS patients who were treated with clopidogrel for at least 5 days. Thromboelastography (TEG) was used to evaluate the platelet function. Clopidogrel HTPR was defined if adenosine diphosphate (ADP)-induced platelet fibrin clot strength (MAADP)> 47 mm. Otherwise, it would be defined as clopidogrel normal on-treatment platelet reactivity (NTPR). Two groups were divided according to admission glucose of 7.8 mmol/L, consistent with previous studies on admission hyperglycemia. The independent risk factors of clopidogrel HTPR were assessed by multivariate logistic regression analysis. Results: A total of 147 patients were evaluated, and 42(28.57%) of patients were identified as clopidogrel HTPR. In the hyperglycemia group (admission glucose level ≥7.8mmol/L), 40.38% patients were defined as clopidogrel HTPR, which was significantly higher than in the normoglycemia group (22.11%, admission glucose level |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
